Abstract
The American Gastroenterological Association's Center for Gastrointestinal Innovation and Technology convened a consensus conference in December 2018, entitled, “Colorectal Cancer Screening and Surveillance: Role of Emerging Technology and Innovation to Improve Outcomes.” The goal of the conference, which attracted more than 60 experts in screening and related disciplines, including the authors, was to envision a future in which colorectal cancer (CRC) screening and surveillance are optimized, and to identify barriers to achieving that future. This White Paper originates from that meeting and delineates the priorities and steps needed to improve CRC outcomes, with the goal of minimizing CRC morbidity and mortality. A one-size-fits-all approach to CRC screening has not and is unlikely to result in increased screening uptake or desired outcomes owing to barriers stemming from behavioral, cultural, and socioeconomic causes, especially when combined with inefficiencies in deployment of screening technologies. Overcoming these barriers will require the following: efficient utilization of multiple screening modalities to achieve increased uptake; continued development of noninvasive screening tests, with iterative reassessments of how best to integrate new technologies; and improved personal risk assessment to better risk-stratify patients for appropriate screening testing paradigms.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2667-2678.e2 |
| Journal | Clinical Gastroenterology and Hepatology |
| Volume | 18 |
| Issue number | 12 |
| DOIs | |
| State | Published - Nov 2020 |
Funding
Joshua Melson (Conceptualization: Lead; Methodology: Lead; Writing – original draft: Lead; Writing – review & editing: Lead);, Thomas F. Imperiale (Conceptualization: Lead; Methodology: Lead; Writing – original draft: Lead; Writing – review & editing: Lead);, Steven H. Itzkowitz (Conceptualization: Equal; Methodology: Equal; Writing – original draft: Equal; Writing – review & editing: Equal);, Xavier Llor (Writing – original draft: Equal; Writing – review & editing: Equal);, Michael L. Kochman (Conceptualization: Equal; Writing – original draft: Equal; Writing – review & editing: Equal);, William M. Grady (Writing – review & editing: Equal);, Robert E. Schoen (Writing – review & editing: Equal);, Carol Burke (Writing – original draft: Equal; Writing – review & editing: Equal);, Aasma Shaukat (Writing – original draft: Equal; Writing – review & editing: Equal);, Linda Rabeneck (Writing – original draft: Equal; Writing – review & editing: Equal);, Uri Ladabaum (Conceptualization: Equal; Methodology: Equal; Writing – original draft: Equal; Writing – review & editing: Lead);, Robert Bresalier (Writing – original draft: Equal; Writing – review & editing: Equal);, Brennan Spiegel (Writing – review & editing: Equal);, Judy Yee (Writing – review & editing: Equal);, Thomas Wang (Writing – review & editing: Equal);, David Lieberman (Conceptualization: Equal; Writing – original draft: Equal; Writing – review & editing: Equal);, Srinadh Komanduri (Conceptualization: Equal; Methodology: Equal; Writing – original draft: Equal; Writing – review & editing: Equal);, V. Raman Muthusamy (Conceptualization: Equal; Methodology: Equal; Writing – original draft: Equal; Writing – review & editing: Equal);, Neelendu Dey (Conceptualization: Equal; Methodology: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Conflicts of interest These authors disclose the following: Joshua E. Melson has received consulting fees from Clinical Genomics, research support from Boston Scientific Corporation, and holds stocks in Virgo Imaging; Xavier Llor has received consulting fees from and served on the advisory board of Exact Sciences; Michael L. Kochman has received consulting fees from Boston Scientific Corporation, Olympus, Pentax, Ferring, and Dark Canyon Laboratories, has stock/ownership interests in Virgo Systems and Dark Canyon Laboratories, and holds stock options in Merck Research Laboratories; William M. Grady has received research funding from Janssen Pharmaceuticals, consulting fees from Boehringer Ingelheim and DiaCarta, and has served on the advisory boards of Freenome, SEngine Precision Medicine, and Guardant Health; Robert E. Schoen has received research funding from Medtronic, Inc; Carol A. Burke has received research funding from Cancer Prevention Pharmaceuticals, Ferring Pharmaceuticals, and Janssen Pharmaceuticals, and has received consulting fees from Freenome, SLA Pharmaceuticals, and Ferring Pharmaceuticals; Uri Ladabaum is an advisor to UniversalDX and Lean, and has received consulting fees from Covidien, MotusGI, Quorum, and Clinical Genomics; Brennan Spiegel has received research support from Alnylam Pharmaceuticals, AstraZeneca, Ironwood Pharmaceuticals, Novartis, Salix Pharmaceuticals, and Shire; Judy Yee has received research funding from EchoPixel, Inc, Philips Healthcare, and GE Healthcare; David Lieberman has received consulting fees from CEGX and Freenome; Srinadh Komanduri has received consulting fees from Boston Scientific Corporation and Medtronic; and V. Raman Muthusamy has received consulting fees from Boston Scientific Corporation, Medtronic, and Medivators, speaking fees from Medtronic and Torax Medical, Inc, and research support from Medtronic. Funding Writing assistance was funded by the American Gastroenterological Association and provided by Peter D. Steinberg. The 2018 AGA CRC summit meeting was supported by the American Gastroenterological Association (AGA); Aries Pharmaceuticals, Inc; Boston Scientific Corporation; Clinical Genomics Pathology, Inc; Cook Medical LLC; Exact Sciences Corporation; GI Supply; Medtronic; Motus GI Holdings, Inc; Olympus America; PENTAX Medical; and Virgo Surgical Video Solutions, Inc. Funding Writing assistance was funded by the American Gastroenterological Association and provided by Peter D. Steinberg. The 2018 AGA CRC summit meeting was supported by the American Gastroenterological Association (AGA); Aries Pharmaceuticals, Inc; Boston Scientific Corporation; Clinical Genomics Pathology, Inc; Cook Medical LLC; Exact Sciences Corporation; GI Supply; Medtronic; Motus GI Holdings, Inc; Olympus America; PENTAX Medical; and Virgo Surgical Video Solutions, Inc.
Keywords
- Adenoma
- Advanced Neoplasia
- Cancer Screening
- Cancer Screening Risk Assessment
- Colonoscopy
- Colorectal Cancer
- Gastrointestinal Cancer Screening
- Polyp
ASJC Scopus subject areas
- Hepatology
- Gastroenterology
